**This article has been corrected:** The correct figure [4C](#F4){ref-type="fig"} is given below:

![**(A)** Illustration of the three predicted p53 binding sites in the SMO promoter. The predicted p53 binding sites are presented in the DNA sequence of the *SMO* promoter (-15000 to -2800). **(B)** HCT116 cells were treated with 200 μM genipin, and then a chromatin immunoprecipitation (ChIP) assay was performed to confirm the direct binding of p53 to the SMO promoter region. **(C)** HCT116 cells were treated with 1 μM MG132 for 6 h and 100 μM Leupeptin for 24 h. GLI1 protein expression of was evaluated by western blotting. **(D)** HCT116 cell lysates were immunoprecipitated with an anti-GLI1 antibody and then immunoblotted with an anti-ubiquitin antibody. **(E)** The interaction between GLI1 and three E3 ligases was measured by co-immunoprecipitation. HCT116 cell lysates were immunoprecipitated with anti-PCAF, anti-β-TrCP, and anti-ITCH antibodies, and then immunoblotted with an anti-GLI-1 antibody. **(F)** HCT116 or p53 knockout (KO) HCT116 cells were treated with 200 μM genipin. Lysates of HCT116 and p53 KO HCT116 cells were immunoprecipitated with an anti-GLI1 antibody and immunoblotted with an anti-ubiquitin antibody. Data are expressed as the means of three independent experiments.](oncotarget-09-28796-g004){#F4}

The authors apologize for the oversight. The authors declare that this correction does not affect the description, interpretation, or the original conclusions of the manuscript.
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